Reports Q3 revenue $389,276 vs $15,884 last year. Improved Cash Position: The Company’s cash and cash equivalents reached $137,344 as of September 30, 2024, up from $60,155 at the end of 2023. Through strategic financing and operational efficiencies, ABVC has strengthened its liquidity to support upcoming anticipated clinical milestones and expansion efforts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVC: